Peter Rule, Chief Executive Officer
Peter Rule has been the CEO of OptiScan Biomedical since 2006 and has served as Chairman of its Board of Directors since 2001.
Before joining OptiScan Biomedical, Mr. Rule was the Chairman and CEO of EKOS Corporation. During his tenure at EKOS he raised over $60 million in venture capital to re-direct product development efforts, resulting in the invention of the company’s peripheral vascular product line, which today generates tens of millions of dollars in revenues. During this period of time, EKOS also conducted an ischemic stroke trial (IMS II) and pioneered a new therapy for the treatment of Hemorrhagic stroke, which has been published (“SLEUTH”). EKOS was sold to BTG for ~$220 million in 2013.
Prior to EKOS, Mr. Rule was the Chairman, CEO and President of PercuSurge, Inc. Mr. Rule raised approximately $50 million for PercuSurge to develop the world’s first embolic protection system for use in interventional cardiology, documenting the product’s efficacy in numerous prospective trials, including a successful 1200 patient randomized trial (“SAFER”) that today remains the largest trial in interventional cardiology run by a venture backed company. During Mr. Rule’s leadership, PercuSurge obtained CE approval and was recommended unanimously for U.S. approval by a panel (which was subsequently granted). PercuSurge was sold to Medtronic for ~$250 million in 2001.
During his tenure at PercuSurge, Mr. Rule was also one of three co-founders of Therasense, Inc., holding the position of Chairman of the Board. Under his leadership, TheraSense raised its first round of funding, recruited the CEO and VP, R & D, and redirected the company’s efforts to focus on the development of the smallest and most accurate hand-held glucose meter for the treatment of outpatient diabetes. The company was later sold to Abbott Laboratories for $1.2 billion.
Prior to PercuSurge, Mr. Rule was the President of MiniMed, Inc. He raised partner and private monies to develop the world’s smallest external insulin pump, growing revenues from zero to $75 million by the year of his departure in 1995. Also under Mr. Rule’s leadership, MiniMed refined its strategy from being an external and implantable insulin pump company, to one of an external pump company with an interstitial fluid sensing continuous glucose meter (cgms), adding the world’s first cgms to its portfolio through internal development. As President, Mr. Rule also completed a successful Initial Public Offering (IPO). The company later sold to Medtronic for $3.7 billion.
During his time at MiniMed, Mr. Rule was an industry advisor to the now famous Diabetes Control and Complications Trial (DCCT). He has over 30 years of experience in the healthcare industry and received his B.S in Economics from the University of Southern California, as well as an MBA from Harvard University.
Donald Webber, Chief Operating Officer
Donald Webber has been the COO of OptiScan since 2010. Between 2007 and 2010, Mr. Webber was VP of Manufacturing Operations at C.R. Bard. Prior to Bard, Mr. Webber was the Vice President of Operations at EKOS Corporation and the President and CEO of Mitralign. Over the last 22 years, Mr. Webber has worked at both public and private sector corporations with annual sales ranging up to $2.8 billion. Mr. Webber has a B.S in Industrial Engineering Technology from State University of New York, and an MBA from Nova Southeastern University.
Patrick Nugent, Chief Financial Officer
Patrick Nugent is the CFO at OptiScan Biomedical. Mr. Nugent has over 16 years of extensive experience in raising capital, strategic and financial planning, audits and investor relations. Prior to joining OptiScan Biomedical, Mr. Nugent held the position of Chief Financial Officer at Pelikan Technologies Inc. Before that Mr. Nugent held the position of Chief Financial Officer and Executive Vice President of Finance for Telesensory Corporation for worldwide operations. Mr. Nugent has a bachelor’s degree in Accounting and Financial Management and is a Chartered Management Accountant from the Chartered Institute of Management Accountants of London, England.
Jim Causey, VP Research & Development
Jim Causey has been the VP, Research & Development of OptiScan since 2012. From 2005 to 2007, Mr. Causey was CEO of M2 Medical Technologies, a medical device start-up developing a next generation insulin pump. Directly prior to joining OptiScan, Mr. Causey had established his own consulting firm.
Mr. Causey was VP of Research & Development at MiniMed Inc. from 1997-2001, responsible for the development of MiniMed’s insulin pump products. While at MiniMed, he led the effort to introduce the most successful insulin pump in MiniMed’s history, either before or after the subsequent acquisition by Medtronic, Inc. Mr. Causey began his career at Pacesetter Systems in 1981, where he participated in and led the development of implantable pacemakers over a period of 15 years. Pacesetter was later acquired by St. Jude Medical. After that acquisition, Mr. Causey held the position of Vice President of Defibrillator Development, leading a team that introduced an industry-leading ICD.
Mr. Causey is a named inventor in over 90 allowed US patents. He has a pre-med Biology degree from CSUN, Northridge, California.